Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GENEDRIVE PLC AGM Information 2018

Jun 11, 2018

7668_rns_2018-06-11_bb8787c3-0f7f-4f3b-80a3-20f6f5b5dc4d.html

AGM Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9477Q

Genedrive PLC

11 June 2018

For release: 11 June 2018

genedrive plc ("genedrive" or the "Company")

Completion of Disposal

Further to the announcement on 14th May 2018 and shareholder approval at the General Meeting on 4th June, genedrive plc is pleased to announce that it has now completed the sale of its contract research and pharmacogenomics divisions for an aggregate cash consideration of up to £1.9m.

-  Ends  -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                         +44 (0)161 989 0245

Matthew Fowler: CFO

Peel Hunt LLP

James Steel                                                                                                                    +44 (0)207 418 8900

Oliver Jackson

Stanford Capital Partners Limited                                                                        +44 (0)203 815 8880

Patrick Claridge               

Consilium Strategic Communications

Chris Gardner                                                                                                                +44 (0)203 709 5700

Matthew Neal

Laura Thornton

[email protected] 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA  and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India.

Further details can be found at: www.genedriveplc.com and www.genedrive.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DISVFLBFVQFLBBX